ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2016
Central serous chorioretinopathy in primary hyperaldosteronism.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Primary hyperaldosteronism in Acute Central Serous Chorioretinopathy: a real need for screening?Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.Eye and vision (London, England) · 2023Review
- Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses.International journal of retina and vitreous · 2022Article
- Response to Letter to the Editor From Behar-Cohen et al.: The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy.The Journal of clinical endocrinology and metabolism · 2022Article
- Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence.Scientific reports · 2021Article
- Central serous chorioretinopathy in active endogenous Cushing's syndrome.Scientific reports · 2021Observational
- Oral medications for central serous chorioretinopathy: a literature review.Eye (London, England) · 2020Review
- Article
- Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.Eye (London, England) · 2019Review
- Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy.JAMA ophthalmology · 2017Article
- Central serous chorioretinopathy: Treatment.Taiwan journal of ophthalmologyReview
- Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe ophthalmological characteristics of 13 patients with primary hyperaldosteronism (PA).
methodsCross-sectional study. All patients underwent extensive ophthalmological examination.
resultsThirteen PA patients (9 male, 4 female) were diagnosed with arterial hypertension for 11.0 ± 11.2 years. Ophthalmological imaging revealed macular serous subretinal fluid (SRF) on optical coherence tomography in 2 patients (15 %). In one of these patients, bilateral chronic central serous chorioretinopathy (CSC) with polypoidal choroidal neovasculopathy was diagnosed, which was effectively treated with full-dose photodynamic therapy. In the other patient with SRF and bilateral diffuse hyperfluorescent areas on fluorescein angiography, the SRF had decreased spontaneously after 6 weeks of follow-up. In 5 of the remaining patients (38 %), retinal pigment epithelium alterations resembling findings characteristic for CSC were seen on multimodal imaging. The mean subfoveal choroidal thickness was 290.2 ± 65.0 μm.
conclusionsRetinal abnormalities resembling (subclinical) CSC are common in patients with PA. These findings indicate that mineralocorticoid-mediated pathways are involved in the pathogenesis of CSC. In CSC patients with hypertension of unknown origin, a diagnosis of PA should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.